Insights on the Role of Diabetes and Geographic Variation in Patients with Criticial Limb Ischaemia

E. Van Belle, S. Nikol, L. Norgren, I. Baumgartner, V. Driver, W. R. Hiatt, J. Belch

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)

    Abstract

    Background: Patients with critical limb ischaemia (CLI) unsuitable for revascularisation have a high rate of amputation and mortality (30% and 25% at 1 year, respectively). Localised gene therapy using plasmid DNA encoding acidic fibroblast growth factor (NV1FGF, riferminogene pecaplasmid) has showed an increased amputation-free survival in a phase II trial. This article provides the rationale, design and baseline characteristics of CLI patients enrolled in the pivotal phase III trial (EFC6145/TAMARIS).

    Methods: An international, double-blind, placebo-controlled, randomised study composed of 525 CLI patients recruited from 170 sites worldwide who were unsuitable for revascularisation and had non-healing skin lesions was carried out to evaluate the potential benefit of repeated intramuscular administration of NV1FGF. Randomisation was stratified by country and by diabetic status.

    Results: The mean age of the study cohort was 70 +/- 10 years, and included 70% males and 53% diabetic patients. Fifty-four percent of the patients had previous lower-extremity revascularisation and 22% had previous minor amputation of the index leg. In 94% of the patients, the index leg had distal occlusive disease affecting arteries below the knee. Statins were prescribed for 54% of the patients, and anti-platelet drugs for 80%. Variation in region of origin resulted in only minor demographic imbalance. Similarly, while diabetic status was associated with a frequent history of coronary artery disease, it had little impact on limb haemodynamics and vascular lesions.

    Conclusions: Clinical characteristics and vascular anatomy of CLI patients with ischaemic skin lesions who were unsuitable for revascularisation therapy show little variations by region of origin and diabetic status. The findings from this large CLI cohort will contribute to our understanding of this disease process.

    This study is registered with ClinicalTrials.gov, number NCT00566657. (C) 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)365-373
    Number of pages9
    JournalEuropean Journal of Vascular and Endovascular Surgery
    Volume42
    Issue number3
    DOIs
    Publication statusPublished - Sep 2011

    Keywords

    • Critical limb ischaemia
    • Gene therapy
    • Risk factors
    • Diabetes
    • PERIPHERAL ARTERIAL-DISEASE
    • CRITICAL LEG ISCHEMIA
    • GROWTH-FACTOR
    • GENE-TRANSFER
    • DOUBLE-BLIND
    • PLASMID
    • ANGIOGENESIS
    • AMPUTATION
    • SURVIVAL
    • THERAPY

    Cite this